Cannabis Up Your Nose?: Exclusive Licensing Deal Signed to Advance Medical Cannabis Delivery

Australian medical technology company Rhinomed has signed a 12-year cannabis licensing agreement with Columbia Care, the largest provider of cannabis-based products in the United States. Rhinomed specializes in anti-snoring nasal delivery technology, but according to the agreement, its nasal platform will now be used by Columbia Care to manufacture a range of products that delivers medical cannabis and other cannabinoid compounds for patients suffering from sleep apnea and PTSD.  

 

Speaking about the future of Rhinomed products in light of the company’s newly-founded relationship with Columbia Care, Rhinomed CEO Michael Johnson said:

“We believe that there is clear medical research support for, and a very real and significant commercial opportunity for nasal stents with medical cannabis formulations. Nasal delivery of cannabinoids opens up a new and exciting market opportunity and has the potential to set a new standard by providing a better and more reliable and repeatable dosing experience.

“This exciting new range of products will sit alongside and complement our existing portfolio – it is an important step in ensuring that Rhinomed technologies deliver on our mission of radically improving the way people breathe, sleep, take medication and maintain their health and wellness.”

By licensing its technology, Rhinomed has removed a key barrier to entry into the still-restricted U.S. medical cannabis market—that is, it’s not actually dealing in pot. In fact, its deal with Columbia Care actually makes Rhinomed the first listed Australian pot stock to open a direct, revenue generating pathway into the U.S. medical cannabis market.

 --Taylor Allan